Is DFTX a good stock to buy right now?

Based on our 6-factor quantitative model, Mind Medicine (MindMed) Inc. (DFTX) receives a "Hold" rating with a composite score of 36.0/100. It is ranked #1,279 out of 4,446 stocks. Key factor scores: Quality 16/100, Value 39/100, Momentum 75/100. The timing signal is "Bullish". This is quantitative analysis only — not investment advice.

What is the stock rating for DFTX?

Mind Medicine (MindMed) Inc. (DFTX) has a "Hold" rating and 3-star score. The composite score of 36.0 ranks it #1,279 among 4,446 U.S. stocks. Ratings are updated weekly using academically-proven factor models.

What sector is DFTX in?

Mind Medicine (MindMed) Inc. operates in the Healthcare sector (Pharmaceutical Products industry) with a market cap of $2.05 billion. It is classified as a mid-cap stock.

Does DFTX pay a dividend?

DFTX does not currently pay a regular dividend. The company may be reinvesting profits for growth.

What is DFTX's P/E ratio?

P/E ratio data is not currently available for DFTX, which may indicate the company is not yet profitable.

How profitable is DFTX?

DFTX's quality factor score is 16/100. ROE: -112.6% vs sector average -43.5%. Margins are moderate to low, reflecting competitive market dynamics.

How is DFTX valued compared to peers?

DFTX's value factor score is 39/100 (higher = cheaper). Key multiples: . Trading at a premium relative to peers.

What is DFTX's debt level?

DFTX's debt-to-equity ratio is 31%. Sector average: 32%. Low leverage suggests conservative financial management.

DFTX has a beta of 1.57, meaning it amplifies market moves. Stability score: 37/100.

Does DFTX have high short interest?

DFTX's short interest factor score is 5/100 (higher = less short selling). Elevated short interest may indicate bearish sentiment or short squeeze potential.

DFTX Stock Analysis: Top Mid-Cap Hold (Score 36.0/100) | Blank Capital Research

Data Series	1D	5D	1M	YTD	1Y	3Y	5Y	10Y
DFTX	+0.51%	+4.11%	+13.02%	+60.79%	+318.87%	-	-	-
Industry Proxy XLV	-1.35%	+0.34%	-3.81%	-4.84%	+9.21%	-	-	-
U.S. Market SPY	-0.07%	+3.60%	+0.34%	-0.36%	+29.52%	-	-	-
Alpha vs Market	+0.58%	+0.51%	+12.68%	+61.15%	+289.35%	-	-	-
Alpha vs Sector	+1.87%	+3.77%	+16.83%	+65.63%	+309.66%	-	-	-

Metric	DFTX	Benchmark
P/E Ratio	-14.0x	-159%
EV/EBITDA	—	—
Price / Book	15.7x

Stock Entity	Score▼	Quality	Value	Momentum	P/E Ratio	ROE	Gross Margin	Net Margin	Rev Growth	D/E Ratio	Market Cap	Compare
AZN ASTRAZENECA PLC	61	43	77	87	45.2x	88.7%	68.6%	28.3%	-	37.0x	$311.3B	VS
SLGL Sol-Gel Technologies Ltd.	57	41	36	98	-	-146.7%	100.0%	-91.7%	-	0.0x	$271M	VS
VMD VIEMED HEALTHCARE, INC.	53	50	63	60	27.6x	9.4%	57.8%	5.4%	30.8%	39.0x	$370M	VS
INVA Innoviva, Inc.	53	50	72	60	15.9x	9.2%	78.6%	23.9%	7.9%	39.0x	$1.7B	VS
HOLX HOLOGIC INC	53	50	43	58	31.7x	10.2%	51.4%	12.9%	3.6%	48.0x	$16.9B	VS
FONR FONAR CORP	52	48	50	57	11.1x	6.5%	88.3%	10.1%	2.4%	33.0x	$117M	VS
JNJ JOHNSON & JOHNSON	52	50	39	65	21.4x	32.9%	67.8%	29.0%	9.3%	51.0x	$588.0B	VS
UTHR UNITED THERAPEUTICS Corp	51	50	63	66	19.4x	18.0%	88.4%	40.7%	11.8%	11.0x	$25.0B	VS
DGX QUEST DIAGNOSTICS INC	51	50	62	55	21.2x	14.2%	33.2%	9.6%	17.5%	79.0x	$21.7B	VS
PFE PFIZER INC	49	50	59	48	11.1x	16.1%	74.7%	22.1%	25.4%	140.0x	$162.4B	VS
DFTX Mind Medicine (MindMed) Inc.	36	16	39	75	-	-112.6%	-	-	-	31.0x	$2.1B

Key Ratio	TTM	2025	2024	2023	2022	2021	2020
Gross Margin %	-	-	-	-	-	-	-
Operating Margin %	-	-	-	-	-	-	-
EBITDA Margin %	-	-	-	-	-	-	-
Net Margin %	-	-	-	-	-	-	-
FCF Margin %	-	-	-	-	-	-	-
ROE %	-1.1%	-0.5%	-0.5%	-1.2%	-0.4%	-0.6%	-0.4%
ROA %	-0.6%	-0.3%	-0.4%	-0.8%	-0.3%	-0.6%	-0.4%
ROIC %	-0.8%	-23.9%	-	-	-597.2%	-409.1%	-

Line Item	TTM	2024	2023	2022	2021	2020
	$0	$0	$0	$0	$0	$0
	$0	$0	$0	$0	$0	$0
	—	$65M	$52M	$36M	$35M	$19M
Depreciation	—	$1M	$3M	$3M	$3M	$0
	-$144M	-$104M	-$94M	-$66M	-$94M	-$33M
EBIT	-$144M	-$104M	-$94M	-$66M	-$94M	-$33M
EBITDA	-$155M	-$119M	-$97M	-$55M	-$91M	-$34M
	—	-$258K	-$5M	-$1M	$359K	$164K
	—	—	—	$0	-$1M	$0
	-$147M	-$109M	-$96M	-$57M	-$93M	-$34M
	$-0.78	$-1.54	$-2.44	$-1.84	$-3.40	$-0.13
Diluted EPS	$-0.78	$-1.54	$-2.44	$-1.84	$-3.40	$-0.13

Mind Medicine (MindMed) Inc. (DFTX) Stock Analysis — April 2026 Rating, Price, and Forecast

Last updated: April 2026

Company Overview — What Does Mind Medicine (MindMed) Inc. Do?

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. It also develops MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company is headquartered in Vancouver, Canada. Mind Medicine (MindMed) Inc. (DFTX) is classified as a mid-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Robert Barrow and employs approximately 40 people. With a market capitalization of $2.1B, DFTX is one of the notable companies in the Healthcare sector.

Mind Medicine (MindMed) Inc. (DFTX) Stock Rating — Hold (April 2026)

As of April 2026, Mind Medicine (MindMed) Inc. receives a Hold rating with a composite score of 36.0/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.DFTX ranks #1,279 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Mind Medicine (MindMed) Inc. ranks among stocks, placing it in the top 10% of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

DFTX Stock Price and 52-Week Range

Mind Medicine (MindMed) Inc. (DFTX) currently trades at $21.84. The stock gained $0.42 (2.0%) in the most recent trading session. The 52-week high for DFTX is $19.62, which means the stock is currently trading 11.3% from its annual peak. The 52-week low is $4.70, putting the stock 364.8% above its annual trough. Recent trading volume was 203K shares, suggesting relatively thin trading activity.

Is DFTX Overvalued or Undervalued? — Valuation Analysis

Mind Medicine (MindMed) Inc. (DFTX) carries a value factor score of 39/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 15.71x, versus the sector average of 2.75x.

At current multiples, Mind Medicine (MindMed) Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Mind Medicine (MindMed) Inc. Profitability — ROE, Margins, and Quality Score

Mind Medicine (MindMed) Inc. (DFTX) earns a quality factor score of 16/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -112.6%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -62.1% versus the sector average of -33.1%.

Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

DFTX Debt, Balance Sheet, and Financial Health

Mind Medicine (MindMed) Inc. has a debt-to-equity ratio of 31.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. Total debt on the balance sheet is $40M. Cash and equivalents stand at $20M.

DFTX has a beta of 1.57, meaning it is more volatile than the broader market — a $10,000 investment in DFTX would be expected to move 57.3% more than the S&P 500 on any given day. The stability factor score for Mind Medicine (MindMed) Inc. is 37/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Mind Medicine (MindMed) Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Mind Medicine (MindMed) Inc. reported revenue of $0 and earnings per share (EPS) of $-0.78. Net income for the quarter was $-147M. Operating income came in at $-144M.

In Q3 2025, Mind Medicine (MindMed) Inc. reported revenue of $0 and earnings per share (EPS) of $-0.78. Net income for the quarter was $-67M. Operating income came in at $-46M.

In Q2 2025, Mind Medicine (MindMed) Inc. reported revenue of $0 and earnings per share (EPS) of $-0.50. Net income for the quarter was $-43M. Operating income came in at $-41M.

In Q1 2025, Mind Medicine (MindMed) Inc. reported revenue of $0 and earnings per share (EPS) of $-0.27. Net income for the quarter was $-23M. Operating income came in at $-32M.

Over the past 8 quarters, Mind Medicine (MindMed) Inc. has experienced revenue contraction from $0 to $0. Investors analyzing DFTX stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

DFTX Dividend Yield and Income Analysis

Mind Medicine (MindMed) Inc. (DFTX) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

DFTX Momentum and Technical Analysis Profile

Mind Medicine (MindMed) Inc. (DFTX) has a momentum factor score of 75/100, indicating strong price momentum with the stock outperforming the majority of the market over recent periods. Stocks with high momentum scores have historically tended to continue their outperformance in the near term. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 5/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

DFTX vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Mind Medicine (MindMed) Inc. (DFTX) ranks #— out of 838 stocks based on the Blank Capital composite score. This places DFTX in the top decile of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing DFTX against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full DFTX vs S&P 500 (SPY) comparison to assess how Mind Medicine (MindMed) Inc. stacks up against the broader market across all factor dimensions.

DFTX Next Earnings Date

No upcoming earnings date has been announced for Mind Medicine (MindMed) Inc. (DFTX) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy DFTX? — Investment Thesis Summary

Mind Medicine (MindMed) Inc. presents a balanced picture with arguments on both sides. The quality score of 16/100 flags below-average profitability. The value score of 39/100 indicates premium valuation. Price momentum is positive at 75/100, suggesting the trend favors buyers. High volatility (stability score 37/100) increases portfolio risk.

In summary, Mind Medicine (MindMed) Inc. (DFTX) earns a Hold rating with a composite score of 36.0/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on DFTX stock.

Related Resources for DFTX Investors

Explore more research and tools: DFTX vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare DFTX head-to-head with peers: DFTX vs AZN, DFTX vs SLGL, DFTX vs VMD.

Business quality

Valuation edge

Market alpha

Unlock Investment Thesis

Unlock Performance & Technicals

Unlock Valuation Tools

Institutional peer matrix

Dispersion: efficiency vs. valuation

Lateral intelligence network

Unlock Financial Statements

Unlock Ownership & Management

Intelligence Feed

Definium Therapeutics to Participate at Upcoming Investor Conferences and Events

Do Definium Therapeutics’ (DFTX) New Hires Hint At A Deeper Bet On Anxiety Treatments?

Definium Therapeutics to Host Investor and Analyst Day in New York on April 22, 2026

Definium Therapeutics Inc (DFTX) Says Cash Enough to Fund Operations into 2028

Weekly Roundup on the Cannabis Sector & Psychedelic Sector

Unlock Earnings Transcripts

Institutional Intelligence FAQ

Related Research & Tools